The 2nd International Workshop on Liver and Gut Fibrosis will take place in Valencia, Spain, on 26-27 October 2023. Organized by the University of Valencia, sponsored by CIBEREHD and FISABIO, and endorsed by major international (EASL, ECCO) and Spanish societies in the field, the workshop is an initiative to bring together basic scientists and clinical experts to share their perspectives about these medical conditions, which constitute a global health problem. The programme will focus on the molecular mechanisms involved in the different types of fibrosis, particularly that found in the gut and liver, with an emphasis on aspects that are common to different organs. In this way, the workshop aims to explore avenues that might lead to an improvement of current therapies and the discovery of new pharmacological approaches.
The event, to be held at ADEIT-Fundació Universitat-Empresa de València, is aimed at clinicians and basic/translational researchers from universities and research institutes, as well as professionals working in hospitals and health services (resident doctors, medical students and nurses).
Registration is now open and abstracts can be submitted from 1st June – 15th July.
For more information consult the website. https://congreso.adeituv.es/fibrosisvalencia2023/
https://twitter.com/pharmacologyvlchttps://www.facebook.com/farmacologiavalenciauv
Background
Fibrosis is a highly prevalent global health problem characterized by an excessive growth of fibrous tissue due to chronic inflammation and altered tissue remodelling and repair processes. It occurs in various organs, including the lung, kidney, liver and intestine, and is a key component of important pathologies, including cystic fibrosis, Crohn’s Disease, ulcerative colitis and Non-Alcoholic Fatty Liver Disease. Despite the huge advances made by research in recent years, the molecular mechanisms involved in the development of fibrosis are still unclear, and seem to vary depending on the organ or tissue affected. Despite its magnitude as a medical problem, there are still very few effective therapeutic options to tackle fibrosis, and only in some organs (lung and kidney), with no specific anti-fibrotic pharmacological treatments currently available for the intestine or liver.
